Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynein axonemal heavy chain 12 (DNAH12) is a large, mammalian-conserved inner dynein arm heavy chain motor protein expressed predominantly in the testes and ciliated tissues including lungs, trachea, and oviducts[1][3]. The protein comprises a N-terminal stem domain crucial for protein-protein interactions and a motor domain with ATPase activity that powers minus-end-directed microtubule movement, essential for sperm motility and flagellar assembly[1][2][3]. DNAH12 interacts with other axonemal dynein components, notably DNALI1 and DNAH1, forming a critical complex for flagellar development and axonemal integrity. Deficiency or mutations in DNAH12 disrupt proper recruitment of interacting components, impair sperm flagella structure, and can result in severe asthenoteratozoospermia or MMAF, manifesting primarily as male infertility but without classic PCD symptoms known for other dynein family members[1][3]. DNAH12 is predicted to lack the microtubule-binding domain present in other dynein heavy chains, marking its unique molecular features within the dynein superfamily[1].
Not applicable (no drugs known to target this protein directly)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynein axonemal heavy chain 12 (DNAH12).